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Asthma in the elderly 
By Professor Gregory Peterson and Dr Mark Naunton 
Case study 
Mrs GH is a 74-year-old lady who was diagnosed with 
asthma four years ago after having an upper respiratory 
infection. She had a hospital admission due to asthma 
about 18 months ago. She is having her prescriptions 
dispensed at the pharmacy; these include Seretide 
MDI 125/25 and Ventdin inhaler, You notice from her 
dispensing history that  she only obtains her asthma 
medication sporadically. You ask Mrs GH how she is  
going with her puffers and asthma in general. She replies 
that she is  'OK, Upon further probing, M r s  Gt i  reveals 
that  she does not think she gets 'that much benefit out 
of the puffers' and she has trouble using them with her 
arthritic hands. She says that she does not get wheezy 
that  often (only every two to three days) and is not sure 
whether she really needs t o  keep using the inhalers. 
'Asthma is under-recognised and undertreated in 
older p~pulations.'~.? 
. Background 
The prevalence of asthma overall in Australia is relatively 
high -it occurs in 14-16% of children and 10-1296 of a d ~ l t s . ~  
It is nor so well known that asthma in elderly people is also 
common and is often undertreated.'" An Australian study 
found a large proportion of those aged over 55 years had 
undiagnosed asthma and that the prevalence of asthma in 
older people may be as high as 15%: while overseas studies 
have similarly indicated that the prevalence of asthma in 
elderly patients may be as high as 17%.2 This is perhaps not 
surprising given that the elderly reportedly complain about 
breathlessness often. A UK survey of older people living in 
A n A u s h a i a n ~ h n d a ~ ~ o f t h o s e a g e d ~ 5 5 y w s  
had utx%gws& a s t m  
of age.Zl2 Older patients with asthma have also been shown 
to deteriorate for longer periods before being admitted to 
hospital with severe acute asthma than younger patients.4 
Underestimation of the severity of an acute exacerbation of 
asthma by both patient and doctor has been suggested as a 
contributory factor to poor outcome in  older people.13 
'Death due to asthma occurs rnostiy in eI&& 
patients. " 
the community found that 33% of those aged above 70 years Asthma definition 
became breathless when walking on the flat in company with 
people their own age.la A population-based study of 6,000 Asthma is a chronic inflammatory disorder of the airways 
men and women aged 65 years and over, performed in 21 with an array of cells, inchding mast cells, eosinophils, 
general practices in Bristol, south west England. found an T lymphocytes, macrophages and neutrophils, playing a 
untreated asthma prevalence of approximately 2.5%. with role in its pathophysiology. In susceptible individuals. 
most subjects (84%) with untreated asthma having moderate this inflammation causes recurrent episodes of wheezing, 
or severe disease." breathlessness, chest tightness and coughing, particularly 
at night and in the early morning. These episodes usually 
'Despite the frequent occurrence of asthma involve airflow obstruction that is often reversible, either 
in the elderk it is a diagnosis that has been spontaneously or with treatment3 The airflow obstruction 
frequently ovefiook& and even when dimvered in asthma is a result of ~Ontraction of the airway smooth 
k is often ur~dertreated, " muscle and swelling of the airway wall due to a combination 
of inflammatory cell infiltration, oedema, smooth muscle Although overall deaths from asthma are declining, this has hypertrophy, and hypersecretion. been most noticeable in vounser ~ e o ~ l e  and children. The 
. - . .  
majority of deaths in Australia in which asthma is listed as Potential triggers for the inflammatory process include allergy, 
the underlying cause are now in people greater than 65 years respiratory infections, gastro-oesophageal reflux disease, 
aged care, 
pathophysiology 
Table 1. Comparison of asthma in the younger versus it is not possible to distinguish asthma from chronic 
elderly patient (modified from Brarnan4) bronchitis, especially in current or former cigarene smokers.4 Distinguishing between asthma and COP0 is difficult and 
Treatment 
Symptoms 
Prognosis 
common I 
Atopy common 1 Mainly intrins~c (non- 
Young 
Mostiy intermittent and 
mild: allergic rlrinitis 
1 atooicl; heqins with I 
Elderly may be impossible in some older patients.'"JU6 Asthma that 
Commonly persistent; has been present for many years, in particular, may lead to 
moderate to severe 1 persistent obstructive ventilatory defect and can mimic COPD.? 
lnterminenl for 1 Need conl~nuovs 
Remission common 
irritants (e.g. tobacco or air pollution), cold air exposure, 
exercise, stress, and some drugs (e.g NSAlDs, p-blockers. 
ACE inhibitors)."The majority of elderly patients who develop 
asthma after age 65 have their first asthmatic symptom 
preceded immediately by, or concomitant with, an upper 
respiratory tract infection.' 
Diagnosis 
'Objective measvres of lung function such as 
spiromety and peak flow measurerrmts are 
generally unden~tilised in elderly patients, and 
this also contributes to the d&y or absence of 
diagmk. " 
A major difficulty in diagnosingasthma in the elderly is 
that the differential diagnosis of breathlessness includes 
many conditions common in older people, e.g. heart failure, 
obesity, malignancy, infection, gastro-oesophageal reflux. 
aspiration, and chronic obstwctive pulmonary disease ICOPO). 
In addition. the elderly may attribute their breathlessness to 
'normal ageing' and not seek help from their doctor? The 
most common symptoms reported are cough, wheezing and 
dyspnoea - similar to younger asthmatics?,' 
In addition, research suggests that doctors are often reluctant 
to use spirometry and measurement of reversibility when 
investigating respiratory symptoms in old people.&l3 This 
leads to a tendency to label breathless or wheezy elderly 
patients as having COP0 rather than asthma. Objective 
measures of pulmonary function can aid in a prompt diagnosis 
?I and lead to effective treatment and improved quality of life.' A simple strategy for the investigation of breathlessness in 
older people should at least include a full blood count, chest 
radiograph. ECG, and spirometry with reversibility.' 
Both men and women who develop asthma after age 40 
usually have prior symptoms of cough and sputum production 
and often have pulmonary function abnormalities before 
being diagnosed with asthma. Thus, in many older patients 
Also. both conditions may be 
If possible, distinguishing asthma from COPD is Important to 
allow appropriate management of the respiratory condition 
and co-morbidities, and accurate prediction of treatment 
response. The two conditions may be differentiated by clinical 
features, particularly age at onset, variability of symptoms 
and nocturnal symptoms in asthma. supported by the results 
of reversibility testing A history of heavy smoking, the 
presence of more prominent lung hyperinflation and chronic 
hypoxaemia favour the diagnosisaf COPD, whereas atopy and 
significant bronchodilator responsiveness favour the diagnosis 
of asthma.I5 
Management of asthma in the eldedy 
The therapeutic approach to asthma in the elderly is much the 
same as for younger asthmatics." but certain aspects take on 
greater importance: difficulty using inhaler devices, concerns 
about osteoporosis with long-term corticosteroid therapy 
(both oral and inhaled), the risk of arrhythmias with p,-agonist 
drugs and the significant side-effects of theophylline.I8 
Studies of asthma in the elderly have shown that, unlike 
many younger adults who often require no medications or 
just as-needed pjagonist therapy for occasional symptoms, 
most older asthmatics need continuous treatment programs to 
control their disease (Table I).' In part, this may be because 
the bronchodilator response to inhaled pjagonists declines 
with age.' Even in mild disease in older adults, regular 
preventive treatment with inhaled corticostemids should be 
considered, given the poor perception of bronchoconstriction 
by older asthmatic patients.' Unfortunately, despite their 
proven efficacy, inhaled corticosteroids are typically 
underused in the elderly asthmatic population!a1718 A large 
US study showed that. among elderly patients with potentia'lly 
life-threatening asthma, only 32% had used preventive 
therapy during the past year?g 
If symptoms persist despite inhaled corticosteroids, addition 
of long-acting p,-agonists should be considered. While the 
elderly with asthma have been under-represented in trials of 
the long-acting p;agonists, there is solid evidence that the 
addition of these agents improves asthma control and allows a 
reduction in the dosage of inhaled cortico~teroids.'~~~ However, 
regular review of cardiovascular status (and monitoring of 
serum potassium concentration) in elderly patients taking 
long-acting 8,-agonists is important.' 
There is no evidence that addition of anticholinergics 
improves control of asthma further i f  the patient does not 
aged care 
IC 
ave co-existing COPD.' Theophylline should be prescribed 
rith extreme caution to  elderly patients with asthma, given 
;s narrow therapeutic margin and the risk of adverse effects 
ncluding nausea and vomiting or sinus and supraventricular 
~chycardias), and its propensity for drug  interaction^.^^ 
Most i~or lant ly for elderly asthrr~tics is a 
-eatrnent regimen thal is as simple as possible? 
nd B bnckod up by a wn'tten se!f-mnanagement 
)Ian thai will improve outcomes.'ie 
Jse of inhaled drug delivery devises 
llder people may be more likely to use asthma medication 
nd devices incorrectly because of vision and cognitive 
n~airment.~' In fact, the great majority of elderly patients 
re unable to properly use metered dose inhalers (MDb), 
ven after instru~tion.~2~ Inadequate timing of actuation and 
ihalation is the most frequent error that is made. Impaired 
~ental  function, weakened or deformed hands, and motor or 
iusculoskeletal diseases are other reasons for inadequate 
11Dl use." Older patients who lack dexterity and grip strength 
2.9. arthritis in the hands, tremor with Parkinson's disease) 
lay have-difficulty with manipulation of an MDI or other 
elivety device {Table 2)."pa 
1 general, patients with cognitive impairment (dementia) 
ril l have most difficulty learning to use the MDI, followed in 
rder by the MDI with spacer, then breath-actuated inhalers 
- i.e, breath-actuated inhalers are preferred." In addition, 
?e elderly may experience difficulties with maintaining an 
dequate seal with their mouth on the inhaler device (e.g. 
ost-stroke or paralysis). Furthermore, the elderly may not 
ave a sufficient inspiratory flow rate which is required to 
eliver a dose of medication from a dry powder inhaler.2a 
atients' perception of their own inhaler skills often 
orrelates poorly with their actual use, highlighting the need 
3 regularly assess inhaler techniq~e.~"~' However. inhaler 
schnique is often not checked in older patients. For a more 
etailed discussion on asthma devices, readers are directed 
3 a previous paper written by one of the authors (Naunton M, 
loggrell S. 1 must see the pharmacist: asthma devices. Aust 
'harm 2007;26(4):302-4). 
he delivery device should be selected individually, based 
n ease of use and cost. Dry powder inhalers may be easier 
3r older patients to use.3 When all MDI is chosen, a spacer 
hould be used.3 The Australian Medicines Handbook has 
etailed descriptions of how each inhalation device should be 
orrectly used. In addition, pharmacists can view how to use 
n MDI and spacer device in the following links, which might 
Iso be useful for patients or carers: 
r www.youtube.com/watch?v=51Zjwcx7Zbs&feaeature=related 
(MDI technique) 
www.youtube.corn/watch?v=OubDEsal7Gw&feature=related 
(animated 3D on how to use MDI) 
www.youtube.com/watch?v=CEUm-zy8xY&feature=related 
(MDI with spacer) 
www.youtube.com/watch?v=oHRTiytvuow&feature=related 
{peak flow meter) 
Steps may need to be taken to simplify inhaler regimens 
for some older people and, where possible, the same 
inhaler device should be prescribed for all the patient's 
inhaled medications. Although currently available inhaled 
corticosteroids are more effective when used twice-daily (with 
the exception of ciclesonide [Aivesco], which can be used 
once-daily), taking the total inhaled corticosteroid dose once 
a day may be an option to aid adherence in stable patients 
with mildlmoderate disease." For example, this might be 
advantageous to those patients with dementia who rely on 
assistance with medications at home by family or carers. 
'Udc!rly people and children have specific 
problems with inhaler use and require both 
targeted and appropriate help in order to 
improvs their inhater technique and minirnj.9~ 
waste of inkled medication and therebre lack 
of therapeutic efect. p9 
Adherence with asthma therapy 
Adherence with asthma therapy is frequently poor in 
elderly  patient^.^^^'."^" Reasons include forgetfulness or 
misunderstanding the correct treatment regimen, and the 
perceived risk of side-effects of inhaled corticosteroids 
(Table 3). Patients are less likely to take their medications 
as prescribed when they think that their asthma symptoms 
are not as severe as the doctor believes them to be. The 
intermittent nature of asthma may lead patients to view 
the disease as an acute condition, rather than a chronic 
illness, resulting in poor adherence to preventive therapy. For 
.Table 2. Patient-related factors to consider when 
choosing a delivery system3 
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example, patients often cease their regular preventive therapy Table 3. Reasons for non-adherence t o  asthma 
once their symptoms have diminished, feeling that they no treatment in elderly patients 
longer require treatment. (modified from Goernan and DouglassZ3) 
Guided self-management of asthma in the 
elderly 
Optimal asthma treatment has adopted the principle of 
'guided self-management', which emphasises recognition of 
worsening symptoms by the patient and self-initiated steps to 
escalate therapy as appropriate and seek emergency care if 
necessary.23 Guided self-management in asthma involves the 
health professional and the patient establishing an asthma 
management plan which is then written down and given to 
the patient for future reference: a written action plan.23 The 
use of guided self-management plans has been associated 
with improved asthma outcomes.31 Unfortunately, Australian 
studies have shown that written action plans are less likety 
to  be provided to older p e ~ p l e . ~  This is despite studies 
demonstrating that older people can and do appreciate self- 
More details on Asthma Management Plans, 
Asthma Cycle of Care, and Asthma Action Plans are briefly 
reviewed by Bereznicki etal. in the current issue of Australian 
Pharmacist (page 41 0). 
'Patient education can be a pamhl  toat h 
asthma control, Family members also can be 
helpful, especial& with etderly adults. Active 
participation by a patient in monitoring Iung 
function, avoidance of provoatia/e agents, 
and decisions regarding medicafions provide 
asthrna management skills that give patients the 
confidence to control their own disease. " 
Pharmacists and asthma management in 
elderly 
Elderly people are less likely to actively seek 
out information about t M r  medication and 
management. * 
Pharmacists are in a pivotal position to contribute to the 
overall management of asthma, given the importance of 
quality use o f  medicines in preventing morbidity and mortality 
in asthma. Pharmacists should make certain that patients or 
their carers understand the purpose and correct use of the 
medication/inhaler device. Simple and clear messages are 
required when counselling all patients with asthma. A quiet 
location (counselling room) is ideal to ensure the correct 
messages are received. In addition, written instructions 
should be given to supplement any discussion. 
Some important points to consider during initial and follow-up 
discussion are as follows. 
Ccmorbidities (deteriorating mental health status, 
deprass~on, vision/heartng loss) 
Problems with device use [stroke, paralysis, arthritis, 
tremor, poor insp~ratory flow) 
Difficulty accessing medical care 
No carer or family help 
Refusal to accept help 
Poor health literacy 
Concern for adverse effects from medication ur actuat 
adverse effects from medication k g .  oral thrush, 
dysphonia, cataracts, glaucoma, osteoporosis) 
Concerns over tolerance, dependence and addiction to 
medication 
Cost of medication 
Lack of belief in effectiveness or necessity of 
medication 
Preference for non-pharmacological treatmsntl 
medication. 
Ensure that the prescribed therapy (and device] is suitable 
and can be used by the patient. 
Regular assessment is  required - encourage regular review 
by doctor. 
Environmental influences such as pdlutinn. air born^ dust, 
smoke, and fumes can induce airway narrowing in patients 
with asthma. Avoidance is  not always possible; however. 
ensuring the home and workplace are relatively free of 
environmental triggers may be useful. 
Encourage the patient to cease smoking. 
Ensure patient understands signs of poorly controlled 
asthma. 
Offer written fact sheets on the principles of asthma 
management, including information about medications and 
potential side effects, ways t o  minirnise asthma triggers, 
and correct device technique. 
A practical demonstration should ALWAYS supplemsnt any 
written information. 
Ask pharmaceutical representatives for demonstration 
models of their products to help patients become familiar 
with drug delivery systems. 
Enquire i f  the patient has an asthma action plan - if not, 
suggest they discuss this on their next scheduled visit to 
their doctor. 
Establish what knowledge about asthma and its therapy Highlight availability of new treatments andlor new 
the patient already possesses. developments in asthma management. if appropriate. 
aged care 
Encourage annual influenza vaccination and five-yemly 
pneurnococcal vaccination in all elderly patients with 
asthma, even in those with mild asthma. 
Attempt to check inhaler technique at every possible 
opportunity. 
Ongoing follow-up of patients with persistent asthma by the 
pharmacist also enables demonstrating and checking inhaler 
technique, re-evaluating the most convenient delivery device, 
making sure that the written action plan is understood, and 
ensuring that any emergency medication (such as a short 
course of oral corticosteroids) is not out of date or lost. A 
number of studies, including several from Australia, have 
demonstrated that community pharmacist-delivered asthma 
care programs can produce beneficial results, with improved 
patient  outcome^.*^ Pharmacists can also request home 
medication review (HMR) referrals from GPs for those patients 
they think would benefit from an educational intervention on 
asthma and a management review, 
When non-adherence is inevitably encountered. it is important 
that pharmacists do not blame patients for non-adherence 
because they can and do make reasoned decisions; rather, 
they should openly discuss the reasons for non-adherence. 
In addition, pharmacists should ensure that any concerns 
regarding drug side effects are discussed in a manner that is 
not alarming. 
Case study 
Returning to our case study, you should provide Mrs GH 
with further information about asthma, emphasising that 
it is a chronic condition that generally requires continuous 
preventive therapy. You suggest that there are other forms of 
respiratory devices available if she is having trouble with the 
inhalers, and offer to discuss this issue with her doctor. You 
could also provide some information about HMRs and suggest 
that she discusses this further with her doctor. Finally, it 
would be worthwhile to ascertain whether she has had her 
annual influenza vaccine. 
'fitlent educatjon in self-management 
techniques and attention to the pmblems 
of adhefence we essential fur kmg-tern? 
management. Ail health care pro@ssionals have 
an important m/e in controlling this common 
disease O7 
Professor Gregory Peterson heads the Unit for Medication Outcomes Research 
and Education. School of Pharmacy, University of Tasmania and was PSA 
Pharmacist of Year for 2007. 
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